Form 4: Gilead Boosts Stake in Assembly Bio with $19.60 Private Placement

Gilead Sciences, a 10% owner and director, acquired additional common stock and warrants in Assembly Biosciences through a private placement.

Summary

• Gilead Sciences, Inc. (Reporting Person) acquired additional securities in Assembly Biosciences, Inc. (Issuer ASMB).
• The transaction, dated August 8, 2025, involved a private placement.
• Gilead acquired 2,295,920 shares of Assembly Biosciences common stock.
• Gilead also acquired 1,147,960 Class A warrants and 1,147,960 Class B warrants.
• The combined price for the common stock and accompanying half warrants was $19.60 per share.
• Following the transaction, Gilead beneficially owns 4,505,391 shares of common stock.
• Class A warrants are exercisable at $21.6 per share and expire on the earlier of August 11, 2030, or 30 days after Assembly Biosciences completes Phase 2 enrollment for ABI-5366.
• Class B warrants are exercisable at $21.6 per share, become exercisable after November 15, 2026, and expire on December 31, 2026, unless terminated earlier by a $75 million non-dilutive capital raise.
• Both warrant classes have a beneficial ownership limitation of 19.99%.

Sentiment

Score: 7

Explanation: A significant strategic investment by a major pharmaceutical company (Gilead) into Assembly Biosciences provides capital and a vote of confidence. While there's dilution, the investment structure with warrants tied to milestones and non-dilutive capital incentives suggests a positive long-term outlook for Assembly Biosciences.

Positives

• Gilead Sciences, a major pharmaceutical company, is increasing its investment in Assembly Biosciences, indicating confidence in the company's future.
• The private placement provides capital to Assembly Biosciences.
• The structure of the Class B warrants incentivizes Assembly Biosciences to secure non-dilutive capital, potentially reducing future shareholder dilution.

Negatives

• The transaction involves dilution for existing shareholders due to the issuance of new shares and warrants.
• The exercise price of the warrants ($21.6) is higher than the combined price of the private placement ($19.60), suggesting a premium for future exercise.
• Class B warrants have a termination condition tied to a non-dilutive capital raise, which could mean they expire unexercised if the condition is met.

Risks

• Class A warrants' expiration is tied to the enrollment completion of a Phase 2 clinical study (ABI-5366 vs. valacyclovir), introducing clinical trial risk.
• Class B warrants' exercisability and termination are contingent on future events, including a potential non-dilutive capital raise and a specific date (November 15, 2026), adding uncertainty.
• The 19.99% beneficial ownership limit on warrant exercise could restrict Gilead's ability to fully convert if it approaches this threshold.

Future Outlook

Gilead's continued strategic investment in Assembly Biosciences is evident, particularly with the acquisition of warrants tied to future clinical trial milestones and capital raising efforts. The structure of the warrants suggests a long-term view on Assembly Biosciences' drug development and financial strategy.

Industry Context

This transaction highlights a trend of larger pharmaceutical companies investing in smaller biotechnology firms, often to gain access to innovative pipelines or technologies. Gilead's investment in Assembly Biosciences, a company focused on HBV and other viral diseases, aligns with the broader pharmaceutical industry's interest in infectious disease treatments. Such strategic investments can provide crucial funding for smaller biotechs while offering larger players potential future assets.

Comparison to Industry Standards

• Private placements with strategic investors like Gilead are common in the biotech industry for funding R&D and clinical trials, similar to deals seen with companies like Pfizer investing in smaller biotechs or Roche partnering with emerging drug developers.
• The use of warrants tied to clinical milestones (Phase 2 enrollment for ABI-5366) is a standard mechanism to align investor interests with development progress, comparable to milestone payments in licensing agreements.
• The beneficial ownership cap (19.99%) is a common anti-takeover or regulatory compliance measure, often seen in strategic investments to avoid triggering certain change-of-control provisions or HSR Act filings.

Related Party Transactions

• Gilead Sciences, as a 10% owner and director of Assembly Biosciences, engaged in a private placement to acquire additional common stock and warrants from the Issuer.

Stakeholder Impact

• Shareholders: Experience dilution from the issuance of new shares and warrants, but benefit from the capital infusion and strategic backing of Gilead.
• Company (Assembly Biosciences): Receives capital for operations and R&D, strengthens its balance sheet, and gains strategic alignment with a major industry player.
• Employees: Potential for increased job security and resources due to improved financial stability.

Next Steps

• Assembly Biosciences is expected to continue its Phase 2 clinical study evaluating ABI-5366 vs. valacyclovir, as its enrollment completion is a trigger for Class A warrant expiration.
• Assembly Biosciences may pursue a collaboration agreement to raise at least $75 million in non-dilutive capital, which would impact the Class B warrants.

Key Dates

Recommendation

Gilead's increased stake in Assembly Biosciences through a private placement signals confidence and provides crucial capital, which is a positive. However, the transaction involves dilution for existing shareholders, and the value realization from the warrants is contingent on future events like clinical trial success and securing non-dilutive capital. This creates a mixed outlook, suggesting a 'hold' for investors to await further operational and clinical developments from Assembly Biosciences before making a more aggressive move.

Keywords

Gilead Sciences, Assembly Biosciences, ASMB, Private Placement, Common Stock, Warrants, SEC Form 4, Biotechnology, Pharmaceuticals, Investment, Clinical Trials, ABI-5366, Equity Financing